secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001493152-22-030817
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q3 2022 net loss improves to $2.3M; cash $57.8M, pipeline on track
--------------------------------------------------------------------------------

- Net loss of $2.3M ($0.21/shr) vs $4.1M ($0.36/shr) in Q3 2021; R&D expenses fell to $0.7M.
- Cash, equivalents and marketable securities $57.8M as of Sep 30, 2022; cash runway into 2025.
- Harmonic Phase 2 trial (LP-300) activated first two US sites; new U.S. patent issued for LP-300 through 2032.
- IND-enabling studies for LP-184 and LP-284 expected complete Q1 2023; Phase 1 launches targeted H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/0001493152-22-030817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315222030817/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer